Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tx Medic AB currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is located in 1 distinct art unit, reflecting a focused technical engagement with the USPTO in a specific area of biotechnology. The company's current prosecution activity is concentrated in this single matter, rather than being distributed across multiple technical groups. The 1 distinct art units involved provide a specialized environment for the examination of the company's current innovations.
The prosecution is overseen by 1 distinct examiners, with BERRY, LAYLA D serving as the busiest examiner. BERRY, LAYLA D is responsible for 1 busiest examiner pending office action, which accounts for the entire active workload of the portfolio. This creates a direct and singular line of communication between the company and the USPTO for its current filings. With 1 pending office action and 1 distinct examiners, the portfolio's immediate progress depends on a single examination cycle.
Practitioners can focus their efforts on the specific requirements and examination style of BERRY, LAYLA D within the Biotechnology & Pharmaceuticals field. This lack of complexity across 1 distinct art units allows for a highly targeted and efficient response strategy. The 1 busiest examiner pending status ensures that all current feedback originates from a single source, allowing for a unified approach to the company's intellectual property. This concentration in a single technology area highlights the company's core technical focus during this prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18781181 | USE OF DEXTRAN SULFATE | BERRY, LAYLA D | 1693 | §103DP | Non-Final OA | — | Pending | Jul 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTx Medic AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla D Berry has the most, with 1 of Tx Medic AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
